Company Name [desc] |
Country |
OT4B |
France |
OSIVAX |
France |
OSE Immunotherapeutics |
France |
Osalia |
France |
Oryzon Genomics, S.A. |
Spain |
ORYX GmbH & Co. KG |
Germany |
Orphix Consulting GmbH |
Germany |
Orphelion AB |
Sweden |
ORPHELIA Pharma |
France |
Orphalan |
France |
ORNYX OÜ |
Estonia |
ORKEO |
France |
Orexa B.V. |
Netherlands |
Oresund Pharma ApS |
Denmark |
Oranda Therapeutics Limited |
Ireland |
Opus Materia Ltd |
Greece |
Optimal Regulatory Solutions, S.L.U. |
Spain |
OPERON, S.A. |
Spain |
Op2Lysis |
France |
OP Pharma SRL |
Italy |
Onni Biotechnologies Oy |
Finland |
onkovis GmbH |
Germany |
Onkogen Kft. |
Hungary |
Oniria Therapeutics S.L. |
Spain |
OneChain Immunotherapeutics, S.L. |
Spain |
One-carbon Therapeutics AB |
Sweden |
OncoZenge AB |
Sweden |
Oncostellae S.L. |
Spain |
Oncoscience GmbH |
Germany |
Oncorena AB |
Sweden |
Oncoral Pharma ApS |
Denmark |
Oncoradiomics S.A. |
Belgium |
Oncopeptides AB (publ) |
Sweden |
Onconova Europe GmbH |
Germany |
OncoNano Medicine Limited |
Ireland |
OncoLize B.V. |
Netherlands |
Oncoinvent AS |
Norway |
Oncoheroes Biosciences S.L. |
Spain |
Oncodesign Precision Medicine |
France |
ONCO-EUROPE Kft. |
Hungary |
|